Novel Soluble Mediators of Innate Immune System Activation in Solid Allograft Rejection

Transplantation. 2022 Mar 1;106(3):500-509. doi: 10.1097/TP.0000000000003834.

Abstract

During the past years, solid allograft rejection has been considered the consequence of either cellular- or antibody-mediated reaction both being part of the adaptive immune response, whereas the role of innate immunity has been mostly considered less relevant. Recently, a large body of evidence suggested that the innate immune response and its soluble mediators may play a more important role during solid allograft rejection than originally thought. This review will highlight the role of novel soluble mediators that are involved in the activation of innate immunity during alloimmune response and solid allograft rejection. We will also discuss emerging strategies to alleviate the aforementioned events. Hence, novel, feasible, and safe clinical therapies are needed to prevent allograft loss in solid organ transplantation. Fully understanding the role of soluble mediators of innate immune system activation may help to mitigate solid allograft rejection and improve transplanted recipients' outcomes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allografts
  • Graft Rejection* / prevention & control
  • Immune System
  • Immunity, Innate
  • Organ Transplantation* / adverse effects
  • Transplantation, Homologous